TP53通路分子遗传学改变与肝细胞癌被引量：4

下载PDF

导出

摘要肝细胞癌是一种常见的恶性肿瘤,TP53突变在其发病机制中有重要作用。在我国大陆地区,约有50%HCC患者携带TP53突变,最常见的是黄曲霉毒素导致的R249S突变。MDM2和p14ARF是TP53通路的两个重要调节因子,近来研究显示MDM2扩增和p14ARF纯合性缺失/启动子甲基化也参与了HCC的发生发展过程。目前,有越来越多关于TP53通路改变在HCC早期诊断、预后和治疗中应用的研究,但还需要更多的研究证实。本文重点介绍了TP53通路分子遗传学改变(包括TP53突变、MDM2扩增和p14ARF纯合性缺失/启动子甲基化)与肝细胞癌发生的关系。

作者王岩黄坚

机构地区首都医科大学附属北京友谊医院肝病中心

出处《实用肝脏病杂志》 CAS 2013年第5期474-477,共4页 Journal of Practical Hepatology

关键词肝细胞癌 TP53 MDM2 P14ARF

分类号 R735.7 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1胡娟,王启军.肝癌患者血清锌指蛋白和p53高表达的临床意义[J].中华实用诊断与治疗杂志,2009,23(5):430-431. 被引量：6
2张俊霞,王岩,赵艳平,张蓓,李嘉,黄坚.中国北方人群p14^(ARF)启动子甲基化与原发性肝癌的临床相关性[J].临床肝胆病杂志,2011,27(10):1051-1054. 被引量：1
3Lun-Xiu Qin Zhao-You Tang,Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai,China.The prognostic molecular markers in hepatocellular carcinoma[J].World Journal of Gastroenterology,2002,8(3):385-392. 被引量：163
4Jyh-Der Leu,I-Feng kin,Ying-Fang Sun,Su-Mei Chen,Chih-Chao Liu,Yi-Jang Lee.Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwan Residents population[J].World Journal of Gastroenterology,2009,15(44):5592-5597. 被引量：6

二级参考文献28

1胡娟,魏敏,张鸣山,谭映军,李勇,王宇,曾化松,景秀京,扬继飞,胡宗海.肝癌组织HCC-X基因表达和相关标志蛋白NMR^1H谱特征[J].第四军医大学学报,2003,24(19):1766-1768. 被引量：3
2Jun Cui,Dong Hua Yang,Xiang Jun Bi,Zi Rong Fan Department of Gastroenterology, Zhujiang Hospital, The First Military Medical University, Guangzhou 510282, Guangdong Province, China.Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology[J].World Journal of Gastroenterology,2001,7(1):136-139. 被引量：16
3Qing Wang~1 Zhi Ying Lin~2 Xiao Li Feng~3 ~1Department of Microbiology,Medical Center of Fudan University.the former Shanghai Medical University,Shanghai 200032,China ~2Liver Cancer Institute,Zhongshan Hospital,Shanghai 200032,China ~3Shanghai Institute of Biochemistry,Academy Sinica,Shanghai 200031,ChinaQing Wang earned master degree from Shanghai Medical University in 1996,now a senior lecturer of microbiology,specialized in the role of oncogcncs on tumor metastasis,having 8 papers published..Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection[J].World Journal of Gastroenterology,2001,7(3):335-339. 被引量：48
4Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量：214
5Maija H Zile.Abnormal β-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China[J].World Journal of Gastroenterology,2001,7(4):542-546. 被引量：22
6W.Michael Korn Division of Gastroenterology and Comprehensive Cancer Canter,University of California San Francisco,San Francisco,CA 94143-0128,USA.Moving toward an understanding of the metastatic process in hepatocellular carcinoma[J].World Journal of Gastroenterology,2001,7(6):777-778. 被引量：13
7Zhong-ZhengZhu,Wen-MingCong,Shu-FangLiu,HuiDong,Guan-ShanZhu,Meng-ChaoWu.Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population[J].World Journal of Gastroenterology,2005,11(2):289-292. 被引量：10
8左超海,高炎明.p14ARF与人类肿瘤[J].海南医学院学报,2005,11(1):78-80. 被引量：3
9Rui-Hong Luo,Zhi-Xin Zhao,Zhi-Liang Gao,Ji-Lu Yao,Xu-Yu Zhou.Risk factors for primary liver carcinoma in Chinese population[J].World Journal of Gastroenterology,2005,11(28):4431-4434. 被引量：27
10Wa L, Zhu H, Nie L, et al. A link between p53 transcriptional activity and p53 degraxation[J]. J Oncogene,2004,23(22) :4032- 4036. 被引量：1

共引文献172

1Deng-Fu Yao,Xin-Hua Wu,Xiao-Qin Su,Min Yao, Wei Wu, Li-Wei Qiu, Li Zou and Xian-Yong Meng The Institute of Clinical Medicine, Nantong University, and Department of Gastroenterology,Affiliated Hospital of Nantong University, Nantong 226001, China,and Nanjing Medical University, Nanjing 210009, China.Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2006,5(3):381-386. 被引量：14
2Wei Wu, Deng-Fu Yao, Li-Wei Qiu, Xin-Hua Wu, Ming Yao, Xiao-Qin Su and Li Zou Nantong, China Research Center of Clinical Molecular Biology, Affiliated Hospital, Nantong University, Nantong 226001, China.Abnormal expression of hepatomas and circulating telomerase and its clinical values[J].Hepatobiliary & Pancreatic Diseases International,2005,4(4):544-549. 被引量：1
3Deng-Fu Yao, Xin-Hua Wu, Yong Zhu, Gong-Sheng Shi, Zhi-Zhen Dong, Deng-Bing Yao, Wei Wu, Li-Wei Qiu and Xian-Yong Meng Nantong, China Research Center of Clinical Molecular Biology , Department of Pathology and Department of Gastroenterology , Affiliated Hos- pital of Nantong University,Department of Diagnostics , and Institute of Neurosciences , Nantong University,Nantong 226001, China.Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2005,4(2):220-226. 被引量：81
4Meng-Biao Qiu, Ji-Xiang Zhang, Liang-Ming Liu, Bang-Dong Gong, Bo-Lin Wu, Shui-Shan Zhu and Yi Wen Nanchang, China Molecular Center, Second Affiliated Hospital of Jiangxi Medical College, Nanchang 330006, China.Inhibitory effects of antisense oligodeoxynu-cleotide on expression of vascular endothelia growth factor by human hepatocarcinoma cells[J].Hepatobiliary & Pancreatic Diseases International,2004,3(4):552-557. 被引量：3
5Deng-Fu Yao, Zhi-Zhen Dong, Deng-Bing Yao, Xin-Hua Wu, Wei Wu, Li-Wei Qiu, Hong-Mei Wang and Xian-Yong Meng Nantong, China Research Center of Clinical Molecular Biology, Affilia- ted Hospital of Nantong University, Nantong 226001 , China ,Insti- tute of Neuroscicnces, Nantong University, Nantong 226001 , China.Abnormal expression of hepatoma- derived γ-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes[J].Hepatobiliary & Pancreatic Diseases International,2004,3(4):564-570. 被引量：17
6赵铭锋,王鲁,许祖德,赵燕,汤钊猷.α干扰素对人高转移肝癌细胞系HCCLM3血管形成因子表达的影响[J].世界华人消化杂志,2004,12(6):1277-1279. 被引量：3
7蒋永芳,苏先狮,龚国忠,何艳,许允.鼠CD40配体基因的克隆及表达[J].世界华人消化杂志,2004,12(6):1349-1352. 被引量：2
8范瑞芳,卫立辛,王维锋,尤天庚,杨家和,杨庆,贾凤岐,江小玲,郭亚军,吴孟超.原发性肝癌细针活检端粒酶活性检测的临床意义[J].中国肿瘤临床,2004,31(15):844-847. 被引量：6
9王平,张柏和,卫立辛,吴孟超.表达FasL的肝癌细胞通过Fas/FasL诱导T淋巴细胞发生凋亡[J].肿瘤,2004,24(5):437-439. 被引量：5
10叶丽虹,秦宵然,张晓东,王洪辉,蒋斯明,王长晔,吴晶辉,朱惠芳,赵轼轩,蔡兵.应用SCID鼠筛选肝癌转移性亚克隆及M-H7402亚细胞系的建立[J].南开大学学报（自然科学版）,2004,37(3):120-124. 被引量：4

同被引文献61

1郭春华,张雅雅,刘蕾,万幼峰.AKT通过C-myc通路调控肝癌HepG2细胞中PTEN蛋白的表达[J].肿瘤,2020,40(2):102-112. 被引量：3
2李广彬.大黄附子汤的药理研究与临床新用[J].中国中医药现代远程教育,2008(8):987-987. 被引量：2
3张林军,郑博.大黄附子汤治疗顽固性便秘验案1则[J].河北中医,2004,26(6):445-445. 被引量：8
4陈伟平,刘笑云,韦继政,钟飞鹏.大黄附子汤灌肠治疗慢性肾功能衰竭20例总结[J].湖南中医杂志,2005,21(4):13-14. 被引量：13
5黄灿,樊嘉,邱双健,周俭,吴志全,汤钊猷.原发性肝癌伴肝外恶性肿瘤32例临床分析[J].中国实用外科杂志,2005,25(12):748-749. 被引量：4
6任彭,刘兆平.细胞色素P450研究概况及其应用[J].食品与药品,2006,8(10A):8-13. 被引量：17
7林小聪,刘新光,陈小文,梁念慈.山奈酚抑制蛋白激酶CK2活性[J].中国生物化学与分子生物学报,2006,22(11):894-901. 被引量：14
8Matsukura S, Miyazaki K, Yakushiji H. Combined loss of expression of 06-methylguanine-DNA methyltrans- ferase and hMLH1 accelerates progression of hepatocel- lular carcinoma [ J ]. J Surg Oncol, 2003, 82 ( 3 ) : 194-200. 被引量：1
9Matsukura S, Soejima H, Nakagawachi T, et al. CpG methylation of MGMT and hMLH1 promoter in hepato- cellular carcinoma associated with hepatitis viral infec- tion[J]. Br J Cancer,2003, 88(4) : 521-529. 被引量：1
10Wani Y, Notohara K, Tsukayama C. Reduced expres- sion of hMLH1 and hMSH2 gene products in high-grade hepatocellular carcinoma [ J ]. Aeta Med Okayama, 2001,55(2) : 65-71. 被引量：1

引证文献4

1王培晓,张庆,张力,张慧,陈虹,黄丽虹.乙肝相关性肝癌MLH1与p53的表达及其意义[J].武警医学,2015,26(6):558-562.
2张丽萍,马晓丽,卢晓梅,孙刚,张莉,姚文兵.新疆地区原发性肝癌肿瘤同时性转移基因差异表达[J].药学与临床研究,2023,31(2):104-109.
3赵金龙,陈国铭,邝梓君,汤顺莉,黄雁,陈子茵,张培婵,刘韵韵,唐纯志.大黄附子汤作用机制的靶标与通路探讨[J].中国中医基础医学杂志,2019,25(4):550-555. 被引量：8
4罗成浩,梁建东.基于网络药理学和分子对接探讨墨旱莲治疗肝损伤作用机制研究[J].药物资讯,2021,10(6):346-355.

二级引证文献8

1Fusheng Liu,Chunyue Yu,Jin Liu,Nadia Johnson,Yin Zhang,Zeqi Su,Chenchen Sun,Xia Ding.Dahuang Fuzi decoction reduces inflammation levels and alleviates intestinal mucosal barrier damage in septic rats[J].Journal of Traditional Chinese Medical Sciences,2020,7(1):37-44. 被引量：3
2Rui Wu,Jiaqi Chen,Zimengwei Ye,Zhufeng Wang.Research progress in the treatment of diabetic kidney disease with Chinese medicine enema[J].Journal of Traditional Chinese Medical Sciences,2021,8(3):205-215. 被引量：2
3施繁莉,吕慧侠,张振海.中药药效物质基础的相对动态性研究进展[J].药学进展,2021,45(11):855-861. 被引量：4
4陈家琪,包丹丹,张悦,岳天祥,张钶,李范珠,朴寄纲.附子-大黄药对治疗阳虚类疾病配伍机制研究进展[J].中草药,2022,53(11):3518-3530. 被引量：11
5谢炎烽,杨丽平,陈壮娜,阮永队.温阳健脾益气活血法治疗初诊2型糖尿病的临床研究[J].广州中医药大学学报,2022,39(8):1769-1774. 被引量：1
6赵瑞占.基于叶天士治痢案探讨通涩法在溃疡性结肠炎中的应用[J].光明中医,2023,38(18):3520-3523.
7傅淑琳,刘培中,张和针,李创鹏(指导).李创鹏从“温少阴,通阳明”论治不明原因发热[J].广州中医药大学学报,2024,41(1):218-224.
8田晓霞,张思奇,杨槟旭,宋幸铃,魏如薇,周亚娜.基于《金匮要略》大黄类方探讨肝癌证治[J].国医论坛,2024,39(3):1-3.

1李子杰,冯慧莲,殷果.三氧化二砷诱导卵巢癌细胞系SKOV3细胞凋亡的作用和机制[J].临床和实验医学杂志,2014,13(6):435-439. 被引量：2
2高娟,董兵卫,张渭波,康炜.膀胱癌中整合素连接激酶及相关信号转导通路分子的表达及意义[J].临床与实验病理学杂志,2014,30(8):892-894. 被引量：1
3杨凌,崔宏伟,师迎旭.胃腺癌中hedgehog通路分子的表达[J].世界最新医学信息文摘,2015,15(37):3-4.
4周海榆,陈刚,唐继鸣,贲晓松,谢亮,张冬坤,叶雄,周子浩.mTOR抑制剂治疗非小细胞肺癌疗效预测初步分析[J].广州医学院学报,2013,41(2):79-83.
5周清.EGFR突变阳性晚期非小细胞肺癌患者厄洛替尼治疗前的EGFR T790M突变和BRCA1 mRNA表达[J].循证医学,2011,11(1):3-3.
6何慧,马艳华,苏波,向姝霖,姜浩,杨邦敏,章硕,夏红,苏琦.二烯丙基二硫对人胃癌MGC803细胞Rac1-Pak1／Rock1通路的影响[J].中国药理学通报,2014,30(3):53-58. 被引量：4
7郭付有,宋来君,孙红卫,韩天旺,冯桥显,游潮.JNK信号传导通路分子在破裂颅内动脉瘤中的表达[J].中华神经外科杂志,2007,23(1):73-75. 被引量：5
8王越希,陈晓梅,晏军,李志平.Twist表达情况与乳腺癌细胞株多药耐药性的相关性研究[J].海南医学院学报,2016,22(7):632-635. 被引量：4
9郑于剑,霍枫,汪邵平,李鹏.肝癌肝移植免疫抑制剂应用[J].肝胆外科杂志,2011,19(5):329-331. 被引量：1
10张惟.WNT10A在肾细胞癌组织中的表达及意义[J].山东医药,2013,53(9):56-57.

实用肝脏病杂志

2013年第5期

浏览历史

内容加载中请稍等...

TP53通路分子遗传学改变与肝细胞癌被引量：4

参考文献4

二级参考文献28

共引文献172

同被引文献61

引证文献4

二级引证文献8

相关作者

相关机构

相关主题

浏览历史

TP53通路分子遗传学改变与肝细胞癌 被引量：4

参考文献4

二级参考文献28

共引文献172

同被引文献61

引证文献4

二级引证文献8

相关作者

相关机构

相关主题

浏览历史

TP53通路分子遗传学改变与肝细胞癌被引量：4